MarketCap
Facebook
X
Telegram
Arena Pharmaceuticals Income Statement 2021-2008 | ARNA
Brief overview of profit and loss at Arena Pharmaceuticals
The comparison covers a five-year financial horizon. The revenue attributed to Arena Pharmaceuticals moved from $69.2 million to $54 thousand between the two endpoints. The total change was −99.9%, with a CAGR of approximately −76.1%. Revenue ended the period on a sustained downward trend.
EBITDA was −269 thousand dollars at the beginning and −620 million dollars at the end of the period (−230542%). Operating performance weakened relative to revenue. EBITDA margin moved from −0.4% to −1148938.9%. Operating return per unit of revenue declined.
The final result was −$22.5 million initially and −$616 million in the final year. Larger losses indicate rising pressure on the business.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The most visible risks are weak sales momentum, a low EBITDA margin and weaker operating efficiency. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.65 B | 4.21 B | 2.26 B | 1.83 M | 1.12 B | 3.45 B | 4.57 B | 7.62 B | 12.8 B | 17.7 B | 2.6 T | - | - | - |
Shares |
60.8 M | 54.8 M | 49.8 M | 47 K | 33 M | 243 M | 241 M | 220 M | 218 M | 197 M | 139 B | 110 M | 84.3 M | - |
Historical Prices |
92.9 | 76.8 | 45.4 | 39 | 34 | 14.2 | 19 | 34.7 | 58.5 | 90.2 | 18.7 | - | - | - |
Net Income |
-616 M | -405 M | 398 M | -29.4 M | -91.4 M | -22.5 M | -108 M | -60.5 M | -19.4 M | -85.5 M | -109 M | -125 M | -153 M | - |
Revenue |
54 K | 37 K | 3 M | 8.65 M | 15.4 M | 69.2 M | 13.4 M | 37 M | 81.4 M | 27.6 M | 12.7 M | 16.6 M | 10.4 M | - |
Gross Profit |
- | 319 K | - | - | - | 109 M | 25.2 M | 29.2 M | 75.2 M | 23.9 M | 4.62 M | - | - | - |
Operating Income |
-624 M | -427 M | 483 M | -145 M | -92 M | -5.26 M | -104 M | -105 M | -22.9 M | -57.1 M | -82.8 M | -96.4 M | -138 M | - |
Interest Expense |
4.16 M | 4.52 M | 4.79 M | 5.7 M | 6.12 M | 6.51 M | 6.83 M | 6.92 M | 7.09 M | 9.12 M | 14.3 M | 21.7 M | 18.7 M | - |
EBITDA |
-620 M | -423 M | 486 M | -141 M | -87.7 M | -269 K | -98.1 M | -96.6 M | -15.2 M | -48.1 M | -72.7 M | -86 M | -127 M | - |
Operating Expenses |
- | 427 M | 324 M | 163 M | 101 M | 97.6 M | 124 M | 134 M | 98.2 M | 81 M | 84 M | - | - | - |
General and Administrative Expenses |
126 M | 103 M | 77.6 M | 45.3 M | 30.3 M | 27.5 M | 30.3 M | 34.1 M | 31.7 M | 26.2 M | 24.2 M | 27.9 M | 25.2 M | - |
All numbers in USD currency
Quarterly Income Statement Arena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | 61.6 M | 61.1 M | 60.8 M | 59.8 M | 58.6 M | 57.8 M | 52.8 M | 50.2 M | 50.2 M | 49.9 M | 49.7 M | 49.5 M | 49.4 M | 49.4 M | 49.3 M | 40 M | 39.3 M | 37.8 M | 30.2 M | 245 M | 24.3 M | 243 M | 243 M | 243 M | 243 M | 242 M | 242 M | 236 M | 220 M | 220 M | 220 M | 219 M | 219 M | 218 M | 218 M | 218 M | 217 M | 214 M | 190 M | 164 K | 146 M | 146 M | 143 M | 122 K |
Net Income |
- | - | - | - | - | -196 M | -146 M | -118 M | -122 M | -97.4 M | -84.9 M | -100 M | -88.3 M | -72.9 M | -61.4 M | 620 M | 68.7 M | -34.3 M | -31.8 M | -32 M | -13.7 M | -32.4 M | -23.3 M | -22.1 M | 38.6 M | -12.4 M | -27.2 M | -21.5 M | -30.5 M | -26.4 M | -26.8 M | -24.3 M | -32.1 M | -10.7 M | 7.48 M | -25.3 M | -23.5 M | -17.2 M | 40.1 M | -18.9 M | -21.3 M | -15.5 M | -22.1 M | -26.6 M | -23.7 M | -22.7 M | -22.9 M | -39.9 M |
Revenue |
- | - | - | - | - | - | - | - | 37 K | 20 K | 262 K | 262 K | 3 M | 1.35 M | 1.02 M | 801 M | 8.65 M | 3.57 M | 3.99 M | 1.76 M | 15.4 M | 7.95 M | 6.49 M | 6.62 M | 69.2 M | 19.2 M | 9.51 M | 9.85 M | 7.75 M | 9.14 M | 9.18 M | 12.3 M | 9.19 M | 8.16 M | 12.8 M | 6.81 M | 6.52 M | 3.58 M | 68.9 M | 2.37 M | 1.94 M | 1.48 M | 22 M | 2.19 M | 2.08 M | 3.46 M | 3.26 M | 3.92 M |
Operating Income |
- | - | - | - | - | -194 M | -144 M | -132 M | - | -98.8 M | -87.8 M | -105 M | - | -79.3 M | -68.6 M | 725 M | -44.6 M | -36 M | -33.2 M | -31 M | - | -32.1 M | -21.2 M | -20.5 M | - | -9.86 M | -26.2 M | -19.2 M | - | -25.2 M | -27 M | -21.7 M | - | -26.2 M | -25.4 M | -23.5 M | - | -19.9 M | 39.9 M | -21 M | - | -19.1 M | 1.86 M | -19.6 M | - | -19.3 M | -20 M | -25.2 M |
Interest Expense |
- | - | - | - | - | 1.03 M | 1.05 M | 1.07 M | - | 1.12 M | 1.14 M | 1.16 M | - | 1.2 M | 1.22 M | 1.24 M | - | 1.42 M | 1.45 M | 1.47 M | - | 1.52 M | 1.54 M | 1.57 M | - | 1.61 M | 1.62 M | 1.68 M | - | 1.68 M | 1.75 M | 1.7 M | - | 1.72 M | 1.74 M | 1.75 M | - | 1.77 M | 1.78 M | 1.79 M | - | 1.8 M | 2.49 M | 3.03 M | - | 3.21 M | 3.18 M | 4.69 M |
EBITDA |
- | - | - | - | - | -192 M | -142 M | -131 M | - | -95.9 M | -85.9 M | -104 M | - | -77 M | -67 M | 725 M | -44.6 M | -33.1 M | -31.3 M | -30 M | - | -27.6 M | -18.2 M | -19 M | - | -2.85 M | -21.5 M | -16.8 M | - | -17.8 M | -22 M | -19.3 M | - | -19.8 M | -21.2 M | -21.5 M | - | -14.1 M | 43.8 M | -19.1 M | - | -12 M | 6.58 M | -17.2 M | - | -11.6 M | -14.8 M | -22.6 M |
General and Administrative Expenses |
- | - | - | - | - | 30.3 M | 31.9 M | 29.5 M | - | 19 M | 22.9 M | 26.4 M | - | 20.4 M | 18.4 M | 16.6 M | - | 10.8 M | 10.4 M | 11.2 M | - | 7.79 M | 7.24 M | 8.16 M | - | 8.59 M | 8.46 M | 6.92 M | - | 9.03 M | 8.84 M | 8.44 M | - | 8.03 M | 9.13 M | 8.04 M | - | 7.76 M | 8.6 M | 7.25 M | - | 7.39 M | 5.22 M | 6.36 M | - | 6.03 M | 6.08 M | 6.89 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Arena Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
